english.prescrire.org > Spotlight > Archives : 2024 > Ivosidenib (Tibsovo°) in the first-line treatment of acute myeloid leukaemia with an IDH1 mutation

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2024 : 1 | 30 | 60

Ivosidenib (Tibsovo°) in the first-line treatment of acute myeloid leukaemia with an IDH1 mutation

 Marketing Authorisations   Ivosidenib has been authorised in the European Union, in combination with azacitidine, for the first-line treatment of adult patients with acute myeloid leukaemia and an IDH1 mutation, for whom high-dose cytotoxic chemotherapy is unsuitable. Due to their concurrent development, the azacitidine + ivosidenib combination has not been compared to the azacitidine + venetoclax combination.
Full article available for download by subscribers (4 pages)

EDITORS' OPINION
Informed choices

There are high hopes for "personalised" cancer therapies. Understandably so, given that their stated aim is to identify characteristics, such as genetic alterations, capable of predicting tumour susceptibility to an antineoplastic drug, and to offer this drug only to the patients who are most likely to benefit...

Full text available for download by subscribers

©Prescrire 1 December 2024

Source: "Ivosidenib (Tibsovo°) in the first-line treatment of acute myeloid leukaemia with an IDH1 mutation" Prescrire Int 2024; 33 (265): 285-288. Subscribers only.

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook Share on Twitter
 
 
See also:

"Venetoclax (Venclyxto°)
as first-line treatment
for acute myeloid
leukaemia"
Prescrire Int 2022;